Quick Answer
Rani Therapeutics Holdings, Inc. reported Total Revenue of $1.63 million for the year ending 2025.
- Rani Therapeutics Holdings, Inc. showed an increase of +58.9% in Total Revenue from 2024 to 2025.
- This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: $60.0 thousand | Q3 2020: $108.0 thousand | Q1 2021: $756.0 thousand | Q2 2021: $1.96 million | Q3 2021: $0.00 | Q2 2022: $0.00 | Q3 2022: $0.00 | Q1 2024: $0.00 | Q2 2024: $0.00 | Q3 2024: $0.00 | Q1 2025: $172.0 thousand | Q2 2025: $0.00 | Q3 2025: $0.00.
- Over the full 6 years of available data (2020 to 2025), Rani Therapeutics Holdings, Inc.'s Total Revenue has grown by 253.5%.
- Historical annual values: Fiscal year 2025: $1.63 million | Fiscal year 2024: $1.03 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $0.00 | Fiscal year 2021: $2.72 million | Fiscal year 2020: $462.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: